Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 plus Bevacizumab or Lenvatinib in Advanced HCC
NCT04741165Phase 2Unknown
- Sponsor
- Taizhou Hanzhong Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in hepatocellular carcinoma (HCC), sponsored by Taizhou Hanzhong Pharmaceuticals. Status: unknown.
02
Drugs
pucotenlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04741165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04741165.